Published in final edited form as:

J Am Chem Soc. 2012 January 18; 134(2): 769–772. doi:10.1021/ja2082334.

Dehydratase-Specific Probes for Fatty Acid and Polyketide Synthases

Fumihiko Ishikawa, Robert W. Haushalter, and Michael D. Burkart*

Department of Chemistry and Biochemistry, University of California, San Diego, 9500 Gilman Drive, California 92093-0358

Abstract

We targeted development of a dehydratase (DH) specific reactive probe that can facilitate detection, enrichment, and identification of DH enzymes in fatty acid synthases (FAS) and polyketide synthases (PKS). The first reported mechanism based inactivator, 3-decynoyl-N-acetylcysteamine (3-decynoyl-NAC), while active against the *Escherichia coli* β -hydroxydecanoyl thiol ester DH FabA, translates poorly to an activity-based probe due to non-specific reactivity of the thioester moiety. Here we describe the design, synthesis and utility of a DH-specific probe that contains a sulfonyl 3-alkyne reactive warhead engineered to avoid hydrolysis or non-enzymatic inactivation. When coupled with a fluorescent tag, this probe targets DH enzymes from recombinant type I and type II FAS and PKS enzyme systems and in whole proteomes. Activity studies, including FabA inactivation and antibiotic susceptibility, suggest that this sulfonyl 3-alkyne scaffold selectively targets a common dehydratase mechanism. These studies indicate that the DH-specific mechanism based probe can greatly accelerate both the functional characterization and molecular identification of virtually any type of FAS and PKS in complex proteomes.

Natural products have served as a primary resource in drug discovery, with a profound number of clinical antibiotics, anticancer, and immunosuppressive agents having been directly or indirectly derived from natural sources.¹ Many of these small molecules are biosynthesized by highly versatile and modular polyketide synthases (PKS) that are structurally and functionally analogous to fatty acid synthase (FAS) systems.² While study of secondary metabolism has been extensively evaluated from a genetic context,³ we have begun a program to develop proteomic techniques for isolating and identifying modular synthases that makes use of contemporary activity based protein profiling methods.⁴ This work aims to address those families of natural products that cannot be understood solely by genetic approaches.⁵ Analogous in importance to the examination of the human proteome in context with the genome, proteomic studies of natural product pathways remains a developing field with an urgent need for new small molecule probes with which to interrogate the proteomes of diverse organisms. Multidomain PKS and FAS enzyme systems are particularly resistant to laboratory evaluation as recombinant enzymes due in part to their large molecular weight and the general intractability of producer organisms to genetic manipulation and heterologous expression.⁶ In addition, complicated organisms such as symbiotic ensembles are not amenable to most genetic sequencing methods that rely on pure, isolable strains. Direct profiling of microbial proteomes complements genetic approaches by allowing us to understand the activity, post-translational modification, and

*Corresponding Author: mburkart@ucsd.edu.

Supporting Information. Supporting figures, procedures for the synthesis of **3a**, **3b**, and **4**, complete gel images, and full experimental details. This material is available free of charge via the Internet at <http://pubs.acs.org>.

protein-protein interactions of these enzymes in their native and dynamic proteomic environments.

We recently developed an orthogonal active site identification system (OASIS) consisting of activity-based probes used to isolate and identify modular synthases.^{4b} A current limitation of our original probe set is the limited number of domains targeted, as more complete set of probes will increase the sensitivity of the OASIS method (Figure 1). As not all domains are present in each PKS and FAS biosynthetic protein, a more complete set of reactive probes may be critical to full identification.⁷ The β -hydroxy-ACP dehydratase (DH) found in all FAS pathways and any PKS whose product contains olefinic or saturated methylene units offers an attractive target for probe design. The enzyme FabA catalyzes two reactions in *E. coli* fatty acid biosynthetic pathway: dehydration of (*R*)-3-hydroxydecanoyl-ACP to (*E*)-2-decenoyl-ACP; and the isomerization of (*E*)-2-decenoyl-ACP to (*Z*)-3-decenoyl-ACP.⁸ 3-Decynoyl-*N*-acetyl cysteamine (3-decynoyl-NAC, **1**, Figure 2) has a historic place in the study of enzyme inhibition. Discovered by Bloch in 1967, **1** was shown to rapidly and irreversibly inactivate FabA in what constituted the first recognized instance of “mechanism-based” or “suicide substrate” inhibitor,⁹ where the enzyme target catalyzes the formation of a covalent bond between the small molecule and an active site residue, thus permanently inactivating the enzyme.

Our studies began by preparing fluorescent probe **2** (Figure 2) in order to adapt this technology to our OASIS system.¹⁰ This probe was evaluated against the cell lysates of various microorganisms, but high levels of background fluorescence were observed (results not shown), presumably due to the nucleophilic cleavage of the thioester bond in **2**, releasing a fluorescent thiol that in turn is capable of forming indiscriminate disulfide linkages with Cys residues in other proteins. This, along with the potential for non-enzymatic isomerization of **2** to its reactive allene, followed by indiscriminate protein labeling, suggested the need for a new design.

In these studies, we found that mechanism-based inhibition of FabA by 3-decynoic acid analogues was strongly dependent on the pK_a of the α -proton of the suicide substrate, and the substitution of the thioester linkage with more stable ester or amide linkages (replacement of the sulfur in **2** in Figure 2 with oxygen or nitrogen) greatly decreased or abolished inhibition of FabA.¹⁰ Replacement of the reactive thioester moiety with a non-hydrolysable sulfone as in probe **3a** (Figure 2) not only eliminated the issue of nucleophilic cleavage but also provided an α -proton with sufficient acidity to avoid non-enzymatic inactivation, yet still facilitate enzymatic activation. To this end, fluorescent inhibitors **3a** and **3b** were synthesized from the convergent assembly of commercially available 2-nonyn-1-ol, cystamine for **3a** (or 3-chloropropylamine for **3b**), and a fluorescent tag (see Supporting Information). In addition, acetylated **4** was prepared to provide an analog to **1** for comparative activity studies.

Our biochemical studies began by examining the ability of **3a** and **3b** to label recombinant FabA. Monitoring by SDS-PAGE analysis shows clear labeling of FabA by both inhibitors **3a** (Figure 3a) and **3b** (Figure 3b) that was abrogated by pre-treatment of FabA with sodium dodecyl sulfate (SDS). Subsequent screening allowed us to identify an optimal pH for each labeling process. As shown in Figure 3a, probe **3a** underwent increased non-specific labeling with increasing pH. In contrast, probe **3b** (Figure 3b) was less affected, suggesting that inclusion of a longer alkyl linker reduced pH effects. We conducted time course studies by evaluating the labeling of FabA at pH 8.0 (Figure 3c) and pH 8.5 (Figure 3d), where maximum labeling was observed at 12 h at pH 8.0 and 6 h pH 8.5. In contrast, hydrolytically-sensitive inhibitor **2** (Figure 2) showed greater non-specific (denaturation insensitive) labeling of FabA with increasing pH (results not shown). The evidence provided

in Figure 3 indicates that the α -proton in probes **3a** and **3b** was accessed by the enzyme and that the improved stability of these probes allowed successful labeling of FabA in basic media (pH $\geq$ 8). The relative labeling of FabA by probe **3b** was estimated as 32.6 % at 12 h at pH 8.0 using a *crypto*-ACP with coupled fluorescent phosphopantetheine analog for a standard of fluorescent intensity (see Figure S1).¹¹

To evaluate the specific activity of these probes against FabA, a spectrophotometric assay that monitored the decrease of crotonyl-CoA at 260 nm was used to determine IC₅₀.¹² Probes **3b** and **4** displayed dose dependent activities against recombinant *E. coli* FabA, with calculated IC₅₀ values of 7.8 ± 1.1 μ M and 5.6 ± 1.0 μ M, respectively (Figure S2). In addition, initial rates of inactivation probe **4** were measured.¹³ As expected, the enzyme inactivation was irreversible. The kinetic parameters k_{inact} and K_i were evaluated to be 0.018 ± 0.004 min⁻¹ and 1.32 ± 0.43 mM, respectively (Figure S3). In light of the precise stereochemical and mechanistic details of FabA inactivation by **1**,⁸ we propose that probes **3a-b** act via the mechanism shown in Scheme 1. α -Deprotonation of a sulfonyl 3-alkyne **5** forms the electrophilic allene **6**, which in turn is modified by an active site histidine residue of FabA (**7** and **8**). The experiments here suggest that decreasing chemical formation of the allenic intermediate by pK_a elevation of the α -proton of the sulfonyl alkyne scaffold successfully retains activity while improving stability against nucleophilic decomposition at pH 6.5-8.5 compared to inhibitor **2**.

Our work with the first-generation DH probe **2** showed cross-reactivity with FabB and FabF of *E. coli* fatty acid synthase (two β -keto-acyl-ACP synthases), as well as non-selective labeling with proteins such as BSA. In contrast, incubation of FabA, FabB, FabF, and BSA with 25 μ M of probe **3b** for 12 h at 37 °C at pH 8.0 or 8.5 resulted in preferential labeling FabA with only modest labeling of FabB and FabF and virtually no labeling of BSA (Figure S4). With knowledge of the differential active site chemistry, this result indicates improved targeting to the DH domains.

We next asked whether **3b** could be used to probe endogenous dehydratase activity in proteomes. We began with an analysis of conditions using probe **3b** incubated with unfractionated *E. coli* lysates to which recombinant FabA had been either added (spiked) or omitted (native) for 12 h at 37 °C at pH 8. Proteins were precipitated with trichloroacetic acid (TCA), washed with cold acetone to remove unreacted probe, and subsequently resolubilized and analyzed by in-gel fluorescence. A concentration-dependent labeling of FabA was seen in the proteomic environment (Figure 4a) that closely resembles results with isolated FabA. Furthermore, pre-treatment of FabA by SDS resulted in an absence protein labeling (Figure 4b). Taken together, these experiments indicate that **3b** is a true mechanism-based inactivator that shows little to no cross-reactivity with other enzymes in the proteome. Also, the increasing specificity and markedly low background of **3b** show that sulfonyl alkyne scaffold is an optimal design for applications seeking to specifically label endogenous dehydratase activity from crude cellular lysates.

To isolate cellular target the probe **3b**, we performed immunoprecipitation (IP) using an antibody targeted the coumarin tag (XRI-TF35 mAb) linked Affi-gel resin.¹⁶ *E. coli* lysate was incubated with **3b**, and labeled proteins were isolated by purification with antibody immobilized resin. SDS-PAGE of the pulldown eluant revealed a band at 23 kDa with silver staining (Figure 4b). This observation was dependent on the concentration of **3b**. A sample of the excised band was submitted for LC-MS/MS protein ID analysis, revealing that it contained the endogenous *E. coli* FabA with over 40% peptide coverage (Figure 4c). These results validate the use of **3b** as a selective isolation and identification tool for dehydratases within the proteomic environment.

Next, we evaluated the ability of probe **3b** to identify a model type I PKS. While the above characterization of **3b** focuses on a type II DH in FabA, the dual-activity dehydratase/isomerase FabA in *E. coli* FAS, the DH domains in type I PKS serve only a dehydratase function and therefore exhibit different active site structure.¹⁴ We chose to investigate labeling of mycocerosic acid synthase (MAS), which produces methyl-branched fatty acids in *Mycobacterium tuberculosis*. MAS is an iterative type I PKS producing C27-C32 mycocerosic acids from straight-chain precursors that contains the domain structure KS-AT-DH-ER-KR-ACP.¹⁵ Recombinant MAS (Figure S6) was successfully labeled by treatment with **3b** (Figure 4c). Treatment of MAS with the KS inhibitor cerulenin prior to administration of **3b** did not result in loss of labeling.¹⁷ The relative maximal labeling of MAS by probe **3b** was estimated as 48.2% at pH 8.0, and 68.1% at pH 8.5. Given that DH in type II FAS and type I PKS possess distinct active site structures, similar labeling patterns suggest that **3b** is sensitive to a shared catalytic mechanism, proton abstraction by an active site His-Asp diad. This sulfonyl alkyne scaffold provides a general activity-based probe for common dehydratase-like enzymes, further suggesting utility for product template (PT) domain in fungal nonreducing PKS¹⁸ and the thioester hydrolase (TH) domain in fungal type I iterative PKS.¹⁹

As an ultimate test of proteomic activity, we evaluated the availability of our dual labeling strategies in a proteomic context by applying them to a model system for type I FAS. The human breast cancer cell line SKBR3 is known to produce FAS at detectable levels, a characteristic phenotype associated with aggressive tumor growth.²⁰ To determine optical labeling conditions and provide additional evidence, SKBR3 cell lysates were adjusted to pH 8.0 or 8.5 and probed with **3b** for 12 h at 37 °C. SDS-PAGE analysis of these reactions shows no distinguishable signal for a high molecular weight (HMW) band at pH 8.0 but specific labeling of HMW band corresponding to the approximate size of the human FAS at pH 8.5 (Figure S7). Pre-incubation with cerulenin did not disrupt labeling (middle lanes, Figure 4d), while denaturation by treatment with SDS greatly decreased labeling (right lanes, Figure 4d). Notably, the HMW FAS protein was the only labeled species in this proteome. This finding corresponds identically to our previous results with a labeled protein from SKBR3 cell lysate using ACP, KS, and TE-specific probes.^{4a}

Finally, given that **1** has been shown to possess antibiotic activity,^{9c} we evaluated the antimicrobial activity of probe **3b** and acetyl derivative **4** (Figures S8-S9). In liquid culture, both **3a** (MIC of 501 μ M, or 238 μ g/ml into μ M) and **4** (MIC of 1235 μ M, or 355 μ g/ml into μ M) delivered antibiotic activity comparable to **1**.^{9c} These results suggest that **3b** and **4** share a common mode of action reducing bacterial growth by targeting dehydratases in live bacterial cells. This, along with the specificity studies demonstrated here, suggests that these probes may also have utility for *in vivo*, as well as *in vitro* applications.

In summary, we demonstrate new tools for the study of DH enzymes in FAS and PKS, in which a DH specific fluorescent probe with novel sulfonyl alkyne scaffold was developed. We demonstrated that this scaffold shows antibiotic activity by selectively targeting DH enzymes. The synthesis of this probe is straightforward, offering easy access to synthetic derivatives, and the scaffold itself is stable to a variety of *in vitro* and *in vivo* conditions. Fatty acid biosynthesis remains an attractive target for the development of novel antimicrobial chemotherapeutics,²¹ and this scaffold could offer immediate development of antibiotic analogs. In addition, we determined optimal conditions for DH labeling and visualization by in-gel fluorescent analysis and established the activity of this probe in both purified proteins and with proteomic samples. Applications of this technique include gel-based inhibitor screens,²² the identification of active-site residues from uncharacterized enzymes,²³ and the selective isolation and identification of DH-containing enzymes. Combinations of this DH probe with other domain-specific probes should improve

detection, enrichment, and high resolution of low-abundance proteins in proteomic samples, which we are currently applying to the discovery of natural product pathways in sequenced and unsequenced organisms.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH GM094924. We thank Rajesh Gokhale (IGIB, India) for providing the MAS expression construct and Majid Ghassemian (UC San Diego) for the protein ID analyses.

REFERENCES

- (1). Walsh CT. *Science*. 2004; 303:1805–1810. [PubMed: 15031493]
- (2). (a) Fischbach MA, Walsh CT. *Chem. Rev.* 2006; 106:3468–3496. [PubMed: 16895337] (b) Smith S, Tsai SC. *Nat. Prod. Rep.* 2007; 24:1041–1072. [PubMed: 17898897]
- (3). Cane DE, Walsh CT, Khosla C. *Science*. 1998; 282:63–68. [PubMed: 9756477]
- (4). (a) Meier JL, Mercer AC, Burkart MD. *J. Am. Chem. Soc.* 2008; 130:5443–5445. [PubMed: 18376827] (b) Meier JL, Niessen S, Hoover HS, Foley TL, Cravatt BF, Burkart MD. *ACS Chem. Biol.* 2009; 4:948–957. [PubMed: 19785476]
- (5). Reyes CP, La Clair JJ, Burkart MD. *Chem. Commun.* 2010; 46:8151–8153.
- (6). Pfeifer BA, Khosla C. *Microbiol. Mol. Biol. Rev.* 2001; 65:106–118. [PubMed: 11238987]
- (7). (a) Jia XY, Tian ZH, Shao L, Qu XD, Zhao QF, Tang J, Tang GL, Liu W. *Chem. Biol.* 2006; 13:575–585. [PubMed: 16793515] (b) Zhang H, White-Phillip JA, Melan on CE 3rd, Kwon HJ, Yu WL, Liu HW. *J. Am. Chem. Soc.* 2007; 129:14670–14683. [PubMed: 17985890]
- (8). (a) Leesong M, Henderson BS, Gilling JR, Schwab JM, Smith JL. *Structure*. 1996; 4:253–264. [PubMed: 8805534] (b) Achwab JM, Li WB, Ho CK, Townsend CA, Salituro GM. *J. Am. Chem. Soc.* 1984; 106:7293–7294.
- (9). (a) Brock DJ, Kass LR, Bloch KJ. *J. Biol. Chem.* 1967; 242:4432–4440. [PubMed: 4863740] (b) Helmkamp GM Jr, Brock DJ, Bloch KJ. *J. Biol. Chem.* 1968; 243:3229–3231. [PubMed: 4872868] (c) Kass LR. *J. Biol. Chem.* 1968; 243:3223–3228. [PubMed: 4968523]
- (10). Meier JL, Haushalter RW, Burkart MD. *Bioorg. Med. Chem. Lett.* 2010; 20:4936–4939. [PubMed: 20620055]
- (11). (a) Clarke KM, Mercer AC, La Clair JJ, Burkart MD. *J. Am. Chem. Soc.* 2005; 127:11234–11235. [PubMed: 16089439] (b) Worthington AS, Burkart MD. *Org. Biomol. Chem.* 2006; 4:44–46. [PubMed: 16357994]
- (12). (a) Schwab JM, Klassen JB, Lin DCT. *Anal. Biochem.* 1985; 150:121–124. [PubMed: 3909843] (b) Sharma SK, Kapoor M, Ramaya TNC, Kumar S, Kumar G, Modak R, Sharma S, Surolia N, Surolia A. *J. Biol. Chem.* 2003; 278:45661–45671. [PubMed: 12930838]
- (13). (a) Kitz R, Wilson IB. *J. Biol. Chem.* 1962; 237:3245–3240. [PubMed: 14033211] (b) Mobashery S, Ghosh SS, Tamura SY, Kaiser ET. *Proc. Natl. Acad. Sci. USA.* 1990; 87:578–582. [PubMed: 2300547]
- (14). (a) Heath RJ, Rock CO. *J. Biol. Chem.* 1996; 271:27795–27801. [PubMed: 8910376] (b) Wu J, Zaleski TJ, Valenzano C, Khosla C, Cane DE. *J. Am. Chem. Soc.* 2005; 127:17393–17404. [PubMed: 16332089]
- (15). (a) Minnikin DE, Kremer L, Dover LG, Besra GS. *Chem. Biol.* 2002; 9:545–553. [PubMed: 12031661] (b) Mathur M, Kolattukudy PE. *J. Biol. Chem.* 1992; 267:19388–19395. [PubMed: 1527058]
- (16). Yu W-L, Guizzunti G, Foley TL, Burkart MD, La Clair JJ. *J. Nat. Prod.* 2010; 73:1659–1666.
- (17). Omura S. *Methods Enzymol.* 1981; 72:520–532. [PubMed: 7031426]
- (18). Crawford JM, Korman TP, Labonte JW, Vagstad AL, Hill EA, Kamari-Bidkorpheh O, Tsai SC, Townsend CA. *Nature*. 2009; 461:1139–1143. [PubMed: 19847268]

- (19). (a) Moriguchi T, Kezuka Y, Nonaka T, Ebizuka Y, Fujii I. *J. Biol. Chem.* 2010; 285:15637–15643. [PubMed: 20304931] (b) Scott AI, Beadling LC, Georgopapadakou NH, Subbarayan CR. *Bioorg. Chem.* 1974; 3:238–248.
- (20). Oskovian B. *Cancer Lett.* 2000; 149:43–51. [PubMed: 10737707]
- (21). Heath RJ, White SW, Rock CO. *Appl. Microbiol. Biotechnol.* 2002; 58:695–703. [PubMed: 12021787]
- (22). Leung D, Hardouin C, Boger DL, Cravatt BF. *Nat. Biotechnol.* 2003; 21:687–691. [PubMed: 12740587]
- (23). Shao L, Qu XD, Jia XY, Zhao QF, Tian ZH, Wang M, Tang GL, Liu W. *Biochem Biophys Res Commun.* 2006; 345:133–139. [PubMed: 16677607]

Figure 1.

Methods for the proteomic analysis of FAS and type I or type II PKS using a DH-specific reactive probe. Modules are comprised of acyl carrier protein (ACP), ketosynthase (KS), acyl-transferase (AT), dehydratase (DH), enoyl reductase (ER), ketoreductase (KR), and thioesterase (TE) domains. Application of a DH specific probe is shown by the reactive coupling of a sphere.

Figure 2.

Structures of DH inhibitors. Fluorescent analog **2** was designed as a direct mimic of 3-decynoyl-*N*-acetyl cysteamine (**1**).¹⁰ Second generation probes **3a** and **3b** retained the mechanism-based activities of **1** and **2** with enhanced hydrolytic stability. The effects of the fluorescent tag were readily evaluated by comparison of **3a** and **3b** to **4**. The functional units in each inhibitor are indicated by color shading, as given by the reactive warhead (red), a linker (green) and a fluorescent tag (blue).

Figure 3.

Labeling of recombinant FabA with probes **3a** and **3b**. (a-b) SDS-PAGE analysis denoting the labeling of 0.1 mg/mL FabA in 100 mM Tris-HCl for 12 h at 37 °C with (a) 25 μ M of probe **3a** or (b) 25 μ M probe **3b**. (c-d) Time course studies on the labeling FabA with probe **3b**. SDS-PAGE analysis denoting the labeling 0.1 mg/mL FabA in 100 mM Tris-HCl at 37 °C with 25 μ M probe **3b** at (c) pH 8 or (d) pH 8.5. For each panel, Φ depicts the fluorescence observed with $\lambda_{\text{ex}} = 370$ nm and $\lambda_{\text{em}} = 460$ nm and Σ denotes total protein content by staining with colloidal Coomassie Blue.

Figure 4.

Proteomic applications of DH-specific reactive probe **3b**. (a) Labeling of K12 *E. coli* lysate spiked with recombinant FabA by **3b**. (b) Silver-stained SDS-PAGE gel depicting immunoprecipitation of FabA from K12 *E. coli* lysate (right two lanes), with purified FabA standard (left lane) and increasing concentrations of probe **3b**. (c) LC/MS-MS analysis identified the isolated band (blue box) as FabA with over 40% peptide coverage. Amino acids of the identified peptides are colored either in red or blue. (d) Labeling of recombinant mycocerosic acid synthase (MAS) from *Mycobacterium tuberculosis*. (e) Labeling of DH domain of type I FAS in human SKBR3 lysate. For each panel, the top image (φ) depicts the fluorescence observed with $\lambda_{\text{ex}} = 370$ nm and $\Phi_{\text{em}} = 460$ nm and the bottom (Σ) denotes total protein content by staining with Colloidal Coomassie Blue Stain. Full gels (Figures S5-S7) and experimental procedures are provided in Supporting Information.

Scheme 1.

Predicted mechanism of enzyme inhibition. Based on the known activity of 3-decynoyl-*N*-acetyl cysteamine, FabA should be inhibited by **5**, which would irreversibly inhibit FabA through formation of an electrophilic allenic intermediate **6**. Alkylation of an active site histidine yields **7** and **8**. R denotes the position of a tag such as in **3b**.